Quick Answer
Zenas BioPharma, Inc. reported Net Income of -$377.74 million for fiscal year 2025.
Zenas BioPharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$377.74M | -140.6% |
| 2024 | -$156.99M | -322.9% |
| 2023 | -$37.12M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$51.50M | -33.4% | +1.4% |
| June 30, 2025 | -$52.22M | -37.5% | -55.6% |
| March 31, 2025 | -$33.57M | -20.8% | +13.0% |
| September 30, 2024 | -$38.61M | -208.4% | -1.7% |
| June 30, 2024 | -$37.98M | -30.7% | -36.6% |
| March 31, 2024 | -$27.80M | -45.6% | -178.1% |
| September 30, 2023 | $35.61M | — | +222.6% |
| June 30, 2023 | -$29.05M | — | -52.1% |
- Zenas BioPharma, Inc. showed a decrease of -140.6% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Zenas BioPharma, Inc.’s net income has declined by 917.5% (from -$37.12 million to -$377.74 million).
- The most recent figure is from Zenas BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: